The FDA approved the combination use of nivolumab (Opdivo) plus ipilimumab (Yervoy) for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (Nexavar), according to Bristol Myers Squibb (BMS).
The agency approved a dose of 1 mg/kg of nivolumab and 3 mg/kg of ipilimumab under accelerated approval, the only dual immunotherapy approved by the FDA in this setting.
“We recognize there is a critical need to provide patients with aggressive forms of cancer, like HCC, new treatment options that may offer clinically meaningful and ultimately durable responses,” Adam Lenkowsky, general manager and head, U.S., Oncology, Immunology, Cardiovascular, Bristol Myers Squibb, said in a press release. “Today’s announcement builds on our legacy in pioneering immunotherapy treatments and is an important step in our commitment to…
